The Long-Term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol

This 2006 case report describes the long-term survival of a patient with metastatic pancreatic cancer following treatment with an integrative protocol centered around intravenous alpha-lipoic acid (ALA) and oral low-dose naltrexone (LDN). Diagnosed with pancreatic cancer and liver metastases and given a poor prognosis, the patient underwent the ALA/LDN regimen